These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 2071261)

  • 1. Binding of alfentanil to human alpha 1-acid glycoprotein, albumin and serum.
    Belpaire FM; Bogaert MG
    Int J Clin Pharmacol Ther Toxicol; 1991 Mar; 29(3):96-102. PubMed ID: 2071261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein binding of itraconazole and fluconazole in patients with chronic renal failure.
    Arredondo G; Martinez-Jorda R; Calvo R; Aguirre C; Suarez E
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):361-4. PubMed ID: 7952798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of serum protein binding of felodipine.
    Valle M; Esteban M; Rodríguez-Sasiaín JM; Calvo R; Aguirre C
    Res Commun Mol Pathol Pharmacol; 1996 Oct; 94(1):73-88. PubMed ID: 8948016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interindividual variability in the concentrations of albumin and alpha-1-acid glycoprotein in patients with renal or liver disease, newborns and healthy subjects: implications for binding of drugs.
    Viani A; Rizzo G; Carrai M; Pacifici GM
    Int J Clin Pharmacol Ther Toxicol; 1992 Apr; 30(4):128-33. PubMed ID: 1572757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of diltiazem to albumin, alpha 1-acid glycoprotein and to serum in man.
    Belpaire FM; Bogaert MG
    J Clin Pharmacol; 1990 Apr; 30(4):311-7. PubMed ID: 2341578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum binding of ketoconazole in health and disease.
    Martínez-Jordá R; Rodriguez-Sasiain JM; Suárez E; Calvo R
    Int J Clin Pharmacol Res; 1990; 10(5):271-6. PubMed ID: 2079384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
    Kiriyama A; Nishiura T; Ishino M; Yamamoto Y; Ogita I; Kiso Y; Takada K
    Biopharm Drug Dispos; 1996 Dec; 17(9):739-51. PubMed ID: 8968527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of bupivacaine to human serum proteins, isolated albumin and isolated alpha-1-acid glycoprotein. Differences between the two enantiomers are partly due to cooperativity.
    Mazoit JX; Cao LS; Samii K
    J Pharmacol Exp Ther; 1996 Jan; 276(1):109-15. PubMed ID: 8558418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methodologic factors influencing plasma binding of alpha-1-acid glycoprotein-bound and albumin-bound drugs.
    Morse DS; Abernethy DR; Greenblatt DJ
    Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):535-9. PubMed ID: 3934087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
    David BM; Ilett KF; Whitford EG; Stenhouse NS
    Br J Clin Pharmacol; 1983 Apr; 15(4):435-41. PubMed ID: 6849779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing serum protein binding of lidocaine in humans.
    McNamara PJ; Slaughter RL; Pieper JA; Wyman MG; Lalka D
    Anesth Analg; 1981 Jun; 60(6):395-400. PubMed ID: 6165258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients.
    Chu JS; Kishion S; Nomura A; Miyazaki K
    Zhongguo Yao Li Xue Bao; 1997 Sep; 18(5):408-10. PubMed ID: 10322928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between human serum albumin and alpha 1-acid glycoprotein in the binding of lidocaine to purified protein fractions and sera.
    Krauss E; Polnaszek CF; Scheeler DA; Halsall HB; Eckfeldt JH; Holtzman JL
    J Pharmacol Exp Ther; 1986 Dec; 239(3):754-9. PubMed ID: 3795040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma drug binding: implications for anesthesiologists.
    Wood M
    Anesth Analg; 1986 Jul; 65(7):786-804. PubMed ID: 3087239
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of alfentanil in chronic renal failure.
    Chauvin M; Lebrault C; Levron JC; Duvaldestin P
    Anesth Analg; 1987 Jan; 66(1):53-6. PubMed ID: 3099599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.
    Pedersen LE; Bonde J; Graudal NA; Backer NV; Hansen JE; Kampmann JP
    Br J Clin Pharmacol; 1987 Jan; 23(1):41-6. PubMed ID: 3814461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities.
    Kishino S; Nomura A; Itoh S; Nakagawa T; Takekuma Y; Sugawara M; Furukawa H; Todo S; Miyazaki K
    Eur J Clin Pharmacol; 2002 Dec; 58(9):621-8. PubMed ID: 12483455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The acute changes in serum binding of disopyramide and flecainide after myocardial infarction.
    Caplin JL; Johnston A; Hamer J; Camm AJ
    Eur J Clin Pharmacol; 1985; 28(3):253-5. PubMed ID: 4007029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered protein binding of quinidine in patients with atrial fibrillation and flutter.
    McCollam PL; Crouch MA; Watson JE
    Pharmacotherapy; 1997; 17(4):753-9. PubMed ID: 9250553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.